SCHEMBL2054438

SCHEMBL2054438

Cc1ccc(CCCCNC(=N)NC(=O)c2nc(Cl)c(N)nc2N)cc1

nearest known ligand 0.54

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SCNN1A P37088 20/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14456662 0.99 SCNN1A (0.54) SCNN1A
SCHEMBL16625864 0.93 SCNN1A (0.46) SCNN1A
SCHEMBL16808735 0.92 SCNN1A (0.54) SCNN1A
SCHEMBL13907673 0.92 SCNN1A (0.54) SCNN1A
SCHEMBL9913772 0.92 SCNN1A (0.64) SCNN1A
SCHEMBL10110642 0.91 SCNN1A (0.49) SCNN1A
SCHEMBL12379741 0.91 SCNN1A (0.53) SCNN1A
SCHEMBL10028705 0.91 SCNN1A (0.65) SCNN1A
SCHEMBL9913777 0.91 SCNN1A (0.57) SCNN1A
SCHEMBL9913768 0.91 SCNN1A (0.65) SCNN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9878988-B2 Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases PARION SCIENCES, INC. (US) 2018-01-30 US disclosed
US-9856224-B2 Stable sodium channel blockers PARION SCIENCES, INC. (US) 2018-01-02 US disclosed
US-20170267649-A1 STABLE SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. (US) 2017-09-21 US disclosed
US-20170267649-A1 STABLE SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. (US) 2017-09-21 US disclosed
US-9656972-B2 Compounds for treatment of cystic fibrosis THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2017-05-23 US disclosed
US-20160159754-A1 COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH 2016-06-09 US disclosed
US-9260398-B2 Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases PARION SCIENCES, INC. (US) 2016-02-16 US disclosed
US-20150099764-A1 DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES PARION SCIENCES, INC. (US) 2015-04-09 US disclosed
US-8980898-B2 Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases PARION SCIENCES, INC. (US) 2015-03-17 US disclosed
US-8980898-B2 Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases PARION SCIENCES, INC. (US) 2015-03-17 US disclosed
US-7745442-B2 Methods of reducing risk of infection from pathogens PARION SCIENCES, INC. (US) 2010-06-29 US disclosed
US-20090227530-A1 SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. (US) 2009-09-10 US disclosed
US-20090062308-A1 METHODS OF USING SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. (US) 2009-03-05 US disclosed
US-20080076782-A1 SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. (US) 2008-03-27 US disclosed
US-7345044-B2 Sodium channel blockers PARION SCIENCES, INC. (US) 2008-03-18 US disclosed
US-7332496-B2 Broncholdilator agents; hydration of mucous membranes; respiratory system disorders PARION SCIENCES, INC. (US) 2008-02-19 US disclosed
US-7332496-B2 Broncholdilator agents; hydration of mucous membranes; respiratory system disorders PARION SCIENCES, INC. (US) 2008-02-19 US disclosed
US-20070265280-A1 METHODS OF USING SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. (US) 2007-11-15 US disclosed
US-7247636-B2 Phenolic guanidine sodium channel blockers PARION SCIENCES, INC. (US) 2007-07-24 US disclosed
US-7241766-B2 Methods of using phenolic guanidine sodium channel blockers PARION SCIENCES, INC. (US) 2007-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160159754-A1 COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS CFTR, ELANE, OTC SCNN1A 87/4885
US-20080076782-A1 SODIUM CHANNEL BLOCKERS HCN4, SCN2B, SCN5A SCNN1A 12/4885
US-20150099764-A1 DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES SCNN1B, SCNN1A, SCNN1G SCNN1A 2/4885
US-20170267649-A1 STABLE SODIUM CHANNEL BLOCKERS SCN1B, SCN2B, CACNA1B SCNN1A 25/4885
US-20070265280-A1 METHODS OF USING SODIUM CHANNEL BLOCKERS SCN1B, KCNN3, SCN2B SCNN1A 30/4885
US-20090227530-A1 SODIUM CHANNEL BLOCKERS HCN4, SCN2B, SCN5A SCNN1A 12/4885
US-20090062308-A1 METHODS OF USING SODIUM CHANNEL BLOCKERS SCN1B, KCNN3, SCN2B SCNN1A 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.